Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR882 in Gout
NCT06846515Phase 3Completed
- Sponsor
- Arthrosi Therapeutics
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pozdeutinurad in gout, sponsored by Arthrosi Therapeutics. Started Mar 2025; status: completed.
02
Drugs
pozdeutinurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT06846515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846515.